A Multimodal Convergent Cohort of Parkinson's Disease at FJMUUH (FJMUUH-PD): Natural History Study
1 other identifier
observational
3,000
1 country
1
Brief Summary
Parkinson's disease (PD) is a common neurodegenerative disorder in middle-aged and elderly individuals, with a global incidence of 2.0% among adults aged 65 and over. Its pathogenesis remains unclear, and effective preventive and therapeutic approaches are lacking. PD severely impairs patients' physical and mental health and quality of life, while also imposing a substantial burden on families and society. This study will enroll patients with idiopathic PD diagnosed in the Department of Neurology, Fujian Medical University Union Hospital, from 2026 to 2036 to establish a research cohort. Using a non-interventional design, participants will undergo long-term follow-up through regular clinical visits, scale-based assessments, imaging examinations, and biological specimen testing. Corresponding data will be collected to build a research platform, aiming to clarify the pattern of disease progression and identify early diagnostic biomarkers. All testing methods are safe and reliable and will not pose additional risks to patients. This study will be conducted in strict compliance with ethical requirements. Prior to enrollment, patients will be fully informed of the study details and will voluntarily provide written informed consent. To mitigate the risk of privacy disclosure, measures including coded management, data encryption, and access restriction will be implemented throughout the study to protect participants' privacy, safeguard their legitimate rights and interests, avoid additional financial burdens, and ensure the study is conducted in a standardized manner. I hereby pledge to protect the personal privacy of all study participants and respect their autonomy. The study will be conducted in accordance with the principles of the Declaration of Helsinki and the Ethical Review Measures for Life Sciences and Medical Research Involving Human Subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2026
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 28, 2026
CompletedFirst Submitted
Initial submission to the registry
May 9, 2026
CompletedFirst Posted
Study publicly available on registry
May 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2035
May 15, 2026
January 1, 2026
9.7 years
May 9, 2026
May 9, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
5-Year and 10-Year Survival Rates and Prognostic Factors in Idiopathic Parkinson's Disease Patients in Southeast China
To estimate the 5-year and 10-year overall survival rates among patients with idiopathic Parkinson's disease in Southeast China, and to analyze the impact of clinical, genetic, and lifestyle factors on survival outcomes.
5 years and 10 years after study enrollment
Longitudinal Disease Progression and Associated Factors in Idiopathic Parkinson's Disease Patients in Southeast China
To characterize the longitudinal progression of idiopathic Parkinson's disease (PD) in patients from Southeast China, and to identify clinical, demographic, and biological factors associated with disease progression, using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III and Hoehn \& Yahr staging as primary measures.
Baseline and every 6 months during the 10-year follow-up period
Secondary Outcomes (2)
Identification of Multimodal Biomarkers for Early Diagnosis and Disease Progression in Parkinson's Disease
Baseline, every 12 months during the 10-year follow-up period
Genetic Profiling of Patients with Idiopathic Parkinson's Disease in Southeast China
Baseline
Study Arms (1)
Idiopathic Parkinson's Disease (PD) Patients
This cohort includes patients diagnosed with idiopathic Parkinson's disease (PD) at the Department of Neurology, Fujian Medical University Union Hospital. This is a non-interventional, prospective observational study. Participants will undergo regular clinical visits, standardized scale assessments, imaging examinations, and biological sample collection for long-term follow-up. No additional investigational interventions will be performed beyond routine clinical care.
Eligibility Criteria
The study population consists of patients with idiopathic Parkinson's disease (PD) diagnosed at the Department of Neurology, Fujian Medical University Union Hospital in Southeast China, according to the 2016 Chinese PD Diagnostic Criteria. Eligible patients will be consecutively enrolled during the study period (2026-2035) and followed up prospectively for up to 10 years.
You may qualify if:
- The diagnosis of Parkinson's disease (PD) will be made according to the Chinese Diagnostic Criteria for Parkinson's Disease (2016) issued by the Parkinson's Disease and Movement Disorders Group of the Neurology Branch of the Chinese Medical Association, with confirmation by at least two neurologists. Eligible patients must meet all of the following criteria:
You may not qualify if:
- Patients meeting any of the following conditions will be excluded from the study:
- Inability to complete assessments using the Unified Parkinson Disease Rating Scale (UPDRS); Inability to complete assessments using the Mini-Mental State Examination (MMSE); History of recurrent stroke causing stepwise deterioration of parkinsonian symptoms; Diagnosis of secondary parkinsonism or Parkinson-plus syndromes; History of recurrent head trauma or confirmed encephalitis; Presence of severe organ dysfunction; Presence of severe endocrine diseases; Presence of hematological disorders; Presence of autoimmune diseases; Current diagnosis of malignant tumors.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fujian Medical University Union Hospital, Department of Neurology
Fujian, Fuzhou, 350000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2026
First Posted
May 15, 2026
Study Start
April 28, 2026
Primary Completion (Estimated)
December 31, 2035
Study Completion (Estimated)
December 31, 2035
Last Updated
May 15, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share